Supernus Pharmaceuticals(US:SUPN) Globenewswire·2025-10-21 21:00Core Insights - Supernus Pharmaceuticals, Inc. is set to announce its third quarter 2025 financial and business results on November 4, 2025, after market close [1] - A conference call will be hosted by the President and CEO, Jack Khattar, and Senior Vice President and CFO, Tim Dec, on the same day at 4:30 p.m. ET to discuss the results [2] - The call will be accessible via a live webcast on the Company's Investor Relations website, with a replay available for 60 days post-call [3] Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for central nervous system (CNS) diseases [4] - The company's neuroscience portfolio includes treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [5]